Mounjaro®
Brand Name: Mounjaro®
Composition: Tirzepatide solution for injection
Manufacturer: Lilly (Eli Lilly and Company)
Product Description
Medical Info
Mounjaro® (tirzepatide), manufactured by Eli Lilly, is a sterile solution supplied as a 2.5 mg / 0.5 mL single-dose vial for once-weekly subcutaneous injection. It is primarily indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirzepatide functions as a dual GIP and GLP-1 receptor agonist, augmenting glucose-dependent insulin secretion, slowing gastric emptying, and reducing food intake. Initiated at this 2.5 mg introductory dose, the treatment requires careful titration under medical supervision to mitigate potential gastrointestinal side effects like nausea or diarrhea.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
